Plasma alemtuzumab levels in patients with chronic lymphocytic leukemia treated with alemtuzumab combined with chemotherapy reflect the efficacy of the treatment: a hypothesis

References

• Lepretre S, Aurran T, Mahé B, . Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood 2012; 119:5104–5110.
   PubMed Web of Science ®Google Scholar
• Elter T, James R, Busch R, . Fludarabine and cyclophosphamide in combination with alemtuzumab (FCCam) in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia. Leukemia 2012 May 15. [Epub ahead of print]
   Web of Science ®Google Scholar
• Geisler CH, van't Veer MB, van Putten W, . Immunochemotherapy with low-dose subcutaneous alemtuzumab (A) plus oral fludarabine and cyclophosphamide (FC) is safe and induces more and deeper complete remissions in untreated patients with high-risk chronic lymphocytic leukemia (CLL) than chemotherapy with FC alone. An early analysis of the randomised phase-III trial HOVON68 CLL trial. Blood 2011;118:(Suppl. 1): Abstract 290.
   Google Scholar
• Mould DR, Baumann A, Kuhlmann J, . Population pharmacokinetics-pharmacodynamics of alemtuzumab (campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br J Clin Pharmacol 2007;64:278–291.
   PubMed Web of Science ®Google Scholar
• Hale G, Rebello P, Brettman LR, . Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 2004;104:948–955.
   PubMed Web of Science ®Google Scholar
• Catovsky D, Richards S, Matutes E, . Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomised controlled trial. Lancet 2007;370:230–239.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Neuberg DS, Grever MR, . Phase 3 trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: us intergroup trial e2997. J Clin Oncol 2007;25:793–798.
   PubMed Web of Science ®Google Scholar
• Eichhorst BF, Busch R, Hopfinger G, . Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006;107:885–891.
   PubMed Web of Science ®Google Scholar
• Montagna M, Avanzini MA, Visai L, . A new sensitive enzyme-linked immunosorbent assay (ELISA) for alemtuzumab determination: development, validation and application. Int J Immunopathol Pharmacol 2007;20:363–371.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, . Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Montillo M, Tedeschi A, Miqueleiz S, . Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol 2006;24:2337–2342.
   PubMed Web of Science ®Google Scholar
• Elter T. Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia. Haematologica 2009;94:150–152.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TJ, Keating MJ, . Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. Cancer 2010;117:116–124.
   PubMed Web of Science ®Google Scholar
• Elter T, Molnar I, Kuhlmann J, . Pharmacokinetics of alemtuzumab and the relevance in clinical practice. Leuk Lymphoma 2008;49:2256–2262.
   PubMed Web of Science ®Google Scholar
• Lin TS, Donohue KA, Byrd JC, . Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. J Clin Oncol 2010;28:4500–4506.
   PubMed Web of Science ®Google Scholar
• Riechmann L, Clark M, Waldmann H, . Reshaping human antibodies for therapy. Nature 1988;332:323–327.
   PubMed Web of Science ®Google Scholar
• Sorror ML, Storer B, Sandmaier BM, . Impacts of cytogenetic abnormalities and prior alemtuzumab on outcomes of patients (pts) with high-risk chronic lymphocytic leukemia (CLL) given nonmyeloablative allogeneic hematopoietic cell transplantation (HCT). Blood 2010;116:(Suppl. 1): Abstract 2364.
   PubMed Web of Science ®Google Scholar
• Ding W, Shanafelt TD, Rabe K, . Alemtuzumab use and survival after reduced intensity allogeneic stem cell transplantation in high-risk chronic lymphocytic leukemia (CLL). Blood 2011;118:(Suppl. 1): Abstract 4152.
   PubMed Web of Science ®Google Scholar
• Müller C, Murawski N, Wiesen MHJ, . The role of sex and weight on rituximab clearance and serum elimination half life in elderly patients with DLBCL. Blood 2012;119:3276–3284.
   PubMed Web of Science ®Google Scholar